跳转至内容
Merck
所有图片(2)

主要文件

查看所有文档

857395P

Avanti

GT-11

N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide, powder

别名:

C8-CPPC, C8-cyclopropenylceramide, GT-11 dihydroceramide desaturase inhibitor

登录查看公司和协议定价
所有图片(2)

About This Item

经验公式（希尔记法）:
C28H53NO3
CAS号:
649767-83-9
分子量:
451.73
分類程式碼代碼:
12352211
NACRES:
NA.25

化驗

>99% (TLC)

形狀

powder

包裝

pkg of 1 × 1 mg (857395P-1mg)

製造商／商標名

Avanti Research™ - A Croda Brand 857395P

脂質類型

bioactive lipids
sphingolipids

運輸包裝

dry ice

儲存溫度

−20°C

SMILES 字串

CCCCCCCCCCCCCCC1=C(C1)[C@@H](O)[C@@H](NC(CCCCCCC)=O)CO

InChI

1S/C28H53NO3/c1-3-5-7-9-10-11-12-13-14-15-17-18-20-24-22-25(24)28(32)26(23-30)29-27(31)21-19-16-8-6-4-2/h26,28,30,32H,3-23H2,1-2H3,(H,29,31)/t26-,28+/m0/s1

InChI 密鑰

AQFQOEPCXZMMDT-XTEPFMGCSA-N

相关类别

一般說明

GT-11 is also termed as C8-cyclopropenylceramide or C8-CPPC.

生化／生理作用

GT-11 is an inhibitor of dihydroceramides (DHCer) desaturase activity.

包裝

5 mL Amber Glass Screw Cap Vial (857395P-1mg)

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

儲存類別代碼

11 - Combustible Solids

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Inhibition of sphingolipid metabolism enhances resveratrol chemotherapy in human gastric cancer cells
Shin K, et al.
Biomolecules & Therapeutics, 20(5), 470-470 (2012)
Gemma Triola et al.
Molecular pharmacology, 66(6), 1671-1678 (2004-09-17)
Dihydroceramide desaturase catalyzes the conversion of the innocuous precursor dihydroceramide into a highly bioactive product ceramide. We studied the effect of N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11), the first inhibitor of this enzyme, in primary cultured cerebellar neurons. Although desaturase was efficiently inhibited (IC50
Bioactive sphingolipids: An overview on ceramide, ceramide 1-phosphate dihydroceramide, sphingosine, sphingosine 1-phosphate
Handbook of Neurochemistry and Molecular Neurobiology:Neural Lipids, 373-383 (2010)
Pau Muñoz-Guardiola et al.
Autophagy, 17(6), 1349-1366 (2020-05-14)
ABTL0812 is a first-in-class small molecule with anti-cancer activity, which is currently in clinical evaluation in a phase 2 trial in patients with advanced endometrial and squamous non-small cell lung carcinoma (NCT03366480). Previously, we showed that ABTL0812 induces TRIB3 pseudokinase

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门